Stay updated on Divarasib Combo in KRAS G12C NSCLC Clinical Trial
Sign up to get notified when there's something new on the Divarasib Combo in KRAS G12C NSCLC Clinical Trial page.

Latest updates to the Divarasib Combo in KRAS G12C NSCLC Clinical Trial page
- Check2 days agoChange DetectedUpdated to v3.0.2 on 2025-09-12, adding a new Study Status Contacts/Locations section (2025-09-11) and removing the old v3.0.1 references and the Back to Top link.SummaryDifference2%
- Check9 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.6%
- Check17 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific state, country, and city information. This indicates a shift towards a more generalized presentation of location data.SummaryDifference35%
- Check24 days agoChange DetectedThe study on Divarasib in combination with other anti-cancer therapies has been updated to reflect a new date of August 17, 2025, replacing the previous date of June 22, 2025.SummaryDifference0.9%
- Check31 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.3%
- Check38 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.3%
Stay in the know with updates to Divarasib Combo in KRAS G12C NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Divarasib Combo in KRAS G12C NSCLC Clinical Trial page.